STO · SOBI.ST
Swedish Orphan Biovitrum AB
SEK 490.20SEK 0.00 (0.0%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
Loading market information…
STO · VITR.ST · SEK
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Vitrolife AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 24.98% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Vitrolife AB (publ)’s forward annual dividend is SEK 1.10 per share, paid annual. The forward yield is 0.96% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Vitrolife AB (publ)’s next earnings report is currently expected on Jan 28, 2027, with estimated earnings per share of SEK 1.13. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vitrolife AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vitrolife AB (publ) is a medical technology company specializing in the development, production, and global sale of products for assisted reproduction. Their comprehensive offering includes a variety of essential tools for fertility treatments, such as oocyte retrieval needles, sperm processing solutions, specialized in vitro fertilization media and oils, and micromanipulation pipettes. The company also provides general labware, incubators, cryopreservation products, and systems for preimplantation genetic testing. Furthermore, Vitrolife delivers advanced equipment, including the EmbryoScope and Primo Vision time-lapse systems, along with dedicated dishes and evaluation software for these platforms. Their technology portfolio extends to Octax laser and imaging systems, as well as environmental monitoring solutions like log and guard systems and wireless sensors. With its headquarters located in Gothenburg, Sweden, Vitrolife maintains a significant international presence, operating across Europe, the Middle East, and Africa; Asia; Japan and the Pacific; and both North and South America. Founded in 1994, the company was initially known as Scandinavian IVF Science before officially changing its name to Vitrolife AB (publ) in 1998.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:42 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 | Jul 17, 2025 | SEK 0.74-33.33% vs estimate | SEK 871.00M-1.77% vs estimate |
|---|
| Q1 2025 | Apr 24, 2025 | SEK 0.74-19.57% vs estimate | SEK 842.00M-4.41% vs estimate |
|---|
| Q4 2024 | Jan 30, 2025 | SEK 1.03-14.17% vs estimate | SEK 959.00M+5.5% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 490.20SEK 0.00 (0.0%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
SEK 273.30SEK 0.00 (0.0%)
Getinge AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.18% below the high.
SEK 340.60SEK 0.00 (0.0%)
Sectra AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.29% below the high.
SEK 281.00SEK 0.00 (0.0%)
Medicover AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.89% below the high.
SEK 679.50SEK 0.00 (0.0%)
Camurus AB’s quoted price sits in the upper half of its reported 52-week range, 5.63% below the high.
SEK 323.80SEK 0.00 (0.0%)
BioArctic AB’s quoted price sits in the upper half of its reported 52-week range, 12.35% below the high.
